Loading DCs with Ag

Cytotherapy

Volumn 6, Issue 2, 2004, Pages 111-121

  Vari, Frank ^a   Hart, D N J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen loading; Dendritic cell; Immunotherapy

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CELL SURFACE RECEPTOR; CERAMIDE; DACTINOMYCIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FC RECEPTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN; MESSENGER RNA; MITOMYCIN C; MONOCLONAL ANTIBODY; MUCIN 1; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL LYSATE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENDOMETRIUM CANCER; GENETIC TRANSFECTION; GLIOMA; HUMAN; HYBRID CELL; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY CARCINOMA; MELANOMA; METHODOLOGY; MOLECULAR BIOLOGY; MONOCYTE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PINOCYTOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VACCINATION;

EID: 2642520623     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410005230     Document Type: Review

References (140)

1. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-8.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
3. Sallusto F, Schaerli P, Loetscher P et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-9.
4. Sallusto F, Palermo B, Lenig D et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999;29:1617-25.
5. Mellman I, Turley SJ, Steinman RM. Antigen processing for amateurs and professionals. Trends Cell Biol 1998;8:231-7.
6. Mattes J, Hulett M, Xie W et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387-93.
7. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
8. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
9. Salgaller ML, Thurnher M, Bartsch G et al. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer 1999;86:2674-83.
10. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
11. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-26.
12. Farris AD, Keech CL, Gordon TP et al. Epitope mimics and determinant spreading: pathways to autoimmunity. Cell Mol Life Sci 2000;57:569-78.
13. Butterfield LH, Ribas A, Dissette VB et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
14. + T cell help. J Exp Med 1997;186:65-70.
15. Hung K, Hayashi R, Lafond-Walker A et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357- 68.
16. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-204.
17. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171:5140-7.
18. + T lymphocytes. Nature 2003;421:852-6.
19. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999;90:1115-24.
20. Ribas A, Bui LA, Butterfield LH et al. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res 1999;19:1165-70.
21. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
22. + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-30.
23. Herr W, Ranieri E, Olson W et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000;96:1857-64.
24. Storkus WJ, Zeh Hj, 3rd, Salter RD et al. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 1993;14:94-103.
25. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
26. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 -binding residues. J Immunol 1996;157:2539-48.
27. Irvine KR, Parkhurst MR, Shulman EP et al. Recombinant virus vaccination against 'self' antigens using anchor-fixed immunogens. Cancer Res 1999;59:2536-40.
28. Chua BY, Healy A, Cameron PU et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 2003;81:67-72.
29. Weigt H, Muhlradt PF, Emmendorffer A et al. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003;207:223-33.
30. Millard AL, Ittelet D, Schooneman F et al. Dendritic cell KLH loading requirements for efficient CD4(+) T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine 2003;21:869-76.
31. Tanigawa K, Takeshita N, Eickhoff GA et al. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 2001;24:493-501.
32. Shimizu K, Thomas EK, Giedlin M et al. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001;61:2618-24.
33. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-803.
34. Hersey P, Menzies SW, Halliday GM et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2003;5:5.
35. Kim SB, Baskar S, Kwak LW In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymph 2003;44:1201-8.
36. Hernando JJ, Park TW, Kohler K et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52.
37. Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
38. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88.
39. Toungouz M, Libin M, Bulte F et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with in age-A1 /A3-positive tumors. J Leukoc Biol 2001;69:937-43.
40. Brossart P, Grunebach F, Stuhler G et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte- macrophage colony-stimulating factor. Blood 1998;92:4238-47.
41. Mackey MF, Gunn JR, Maliszewsky C et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161:2094-8.
42. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-72.
43. Chen HW, Huang HI, Lee YP et al. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment. Cancer Immunol Immunother 2002;51:341-8.
44. Melief CJ, Van Der Burg SH, Toes RE et al. Effective therapeutic anticancer vaccines based on precision guiding of cyrolytic T lymphocytes. Immunol Rev 2002;188:177-82.
45. Santin AD, Bellone S, Palmieri M et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPVl6 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003;89:271-80.
46. Paglia P, Chiodoni C, Rodolfo M et al. Murine dendritic cells loaded in vitro with soluble protein prime cvtotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-22.
47. Morse MA, Clay TM, Colling K et al. HER2 dendritic cell vaccines. Clin Breast Cancer 2003;3:S164-72.
48. Berberich C, Ramirez-Pineda JR, Hambrecht C et al. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003;170:3171-9.
49. Lee G, Delohery TM, Ronai Z et al. A comparison of techniques for introducing macromolecules into living cells. Cytometry 1993;14:265-70.
50. Enders GA. Mechanism of antigen presentation after hypertonic loading of soluble antigens. Immunology 2002;106:511-6.
51. Norbury CC, Chambers BJ, Prescott AR et al. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 1997;27:280-8.
52. Mitchell DA, Nair SK, Gilboa E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur J Immunol 1998;28:1923-33.
53. Vlad AM, Muller S, Cudic M et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex Class II-restricted T cells. J Exp Med 2002;196:1435-46.
54. Rodriguez A, Regnault A, Kleijmeer M et al. Selective transport of internalized antigens to the cytosol for MHC Class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-8.
55. Guyre CA, Barreda ME, Swink SL et al. Colocalization of Fc gamma RI-targeted antigen with Class I MHC: implications for antigen processing. J Immunol 2001;166:2469-78.
56. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
57. Akiyama K, Ebihara S, Yada A et al. Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003;170:1641-8.
58. Berlyn KA, Schultes B, Leveugle B et al. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 2001;101:276-83.
59. Sallusto F, Cella M, Danieli C et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex Class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
60. Apostolopoulos V, Barnes N, Pietersz GA et al. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000;18:3174-84.
61. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-79.
62. Hertz CJ, Kiertscher SM, Godowski PJ et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001;166:2444-50.
63. Schjetne KW, Thompson KM, Aarvak T et al. A mouse C(kappa)-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol 2002;14:1423-30.
64. Melcher A, Todryk S, Hardwick N et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-7.
65. Arnold-Schild D, Hanau D, Spehner D et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999;162:3757-60.
66. Todryk S, Melcher AA, Hardwick N et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-408.
67. + T cells in vivo. Proc Natl Acad Sci USA 1994;91:3077-81.
68. Noessner E, Gastpar R, Milani V et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169:5424-32.
69. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
70. Lambert LA, Gibson GR, Maloney M et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-6.
71. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer 2001;91:749-56.
72. Mulders P, Tso CL, Gitlitz B et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999;5:445-54.
73. Thurnher M, Rieser C, Holtl L et al. Dendritic cell-based immunotherapy of renal cell carcinoma. Urol Int 1998;61:67-71.
74. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001;30:33-45.
75. Santin AD, Hermonat PL, Ravaggi A et al. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-9.
76. Santin AD, Hermonat PL, Ravaggi A et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest 2000;49:194-203.
77. Ni HT, Spellman SR, Jean WC et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001;51:1-9.
78. Sauter B, Albert ML, Francisco L et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
79. Basu S, Binder RJ, Suto R et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12:1539-46.
80. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
81. Subklewe M, Paludan C, Tsang ML et al. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med 2001;193:405-11.
82. Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188:2163-73.
83. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce Class I-restricted CTLs. Nature 1998;392:86-9.
84. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extra-cellular calcium. Eur J Immunol 1997;27:1893-900.
85. + T cells for efficient tumor cell lysis. Cancer Res 2000;60:4446-52.
86. Hoffmann TK, Meidenbauer N, Muller-Berghaus J et al. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 2001;24:162-71.
87. Hoffmann TK, Meidenbauer N, Dworacki G et al. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60:3542-9.
88. Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-68.
89. Ronchetti A, Rovere P, Iezzi G et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999;163:130-6.
90. Chang JW, Peng M, Vaquerano JE et al. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 2000;20:1329-36.
91. Chen Z, Moyana T, Saxena A et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001;93:539-48.
92. Schnurr M, Scholz C, Rothenfusser S et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 2002;62:2347-52.
93. Lambert LA, Gibson GR, Maloney M et al. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 2001;24:232-6.
94. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105-9.
95. Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-5.
96. O'Rourke MG,Johnson M, Lanagan C et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95.
97. Goddard RV, Prentice AG, Copplestone JA et al. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 2003;131:82-9.
98. Tanaka H, Shimizu K, Hayashi T et al. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002;220:1-12.
99. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
100. Gong J, Chen D, Kashiwaba M et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
101. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000;97:2715-8.
102. Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165:1705-11.
103. Liu Y, Zhang W, Chan T et al. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res 2002;26:757-63.
104. Brossart P, Goldrath AW, Butz EA et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997;158:3270-6.
105. Szabolcs P, Gallardo HE Ciocon DH et al. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 1997;90:2160-7.
106. Jenne L, Hauser C, Arrighi JF et al. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther 2000;7:1575-83.
107. Strobel I, Krumbholz M, Menke A et al. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector. Hum Gene Ther 2000;11:2207-18.
108. Cella M, Salio M, Sakakibara Y et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999;189:821-9.
109. Kaplan JM, Yu Q, Piraino ST et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
110. Rea D, Schagen FH, Hoeben RC et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999;73:10245-53.
111. Morelli AE, Larregina AT, Ganster RW et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappa B-dependent pathway. J Virol 2000;74:9617-28.
112. Reeves ME, Royal RE, Lam JS et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996;56:5672-7.
113. Kim CJ, Prevette T, Cormier J et al. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother 1997;20:276-86.
114. + T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 1999;162:144-51.
115. Ribas A, Butterfield LH, Hu B et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000;23:59-66.
116. Ribas A, Butterfield LH, McBride WH et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997;57:2865-9.
117. Song W, Tong Y, Carpenter H et al. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther 2000;7:2080-6.
118. Song W, Kong HL, Carpenter H et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997;186:1247-56.
119. McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998;21:41-7.
120. Wan Y, Emtage P, Zhu Q et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999;198:131-8.
121. Check E. Second cancer case halts gene-therapy trials. Nature 2003;421:305.
122. Boczkowski D, Nair SK, Snyder D et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
123. Boczkowski D, Nair SK, Nam JH et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-34.
124. Heiser A, Dahm P, Yancey DR et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000;164:5508-14.
125. Heiser A, Maurice MA, Yancey DR et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388-93.
126. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17.
127. Nair SK, Boczkowski D, Morse M et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16:364-9.
128. Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-7.
129. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002;259:191-203.
130. Van Tendeloo VF, Ponsaerts P, Lardon F et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
131. Muller MR, Grunebach F, Nencioni A et al. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 2003;170:5892-6.
132. Kalady MF, Onaitis MW, Padilla KM et al. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res 2002;105:17-24.
133. Grunebach F, Muller MR, Nencioni A et al. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003;10:367-74.
134. Heiser A, Maurice MA, Yancey DR et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001;166:2953-60.
135. Milazzo C, Reichardt VL, Muller MR et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003;101:977-82.
136. Nair SK, Hull S, Coleman D et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999;82:121-4.
137. Ashley DM, Faiola B, Nair S et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
138. + cytotoxic T lymphocytes. FEBS Lett 1998;441:353-6.
139. Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000;30:848-57.
140. Serre K, Machy P, Grivel JC et al. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J Immunol 1998;161:6059-67.